# EDGAR Filing Document

**Accession Number:** 0001835579
**File Stem:** 0001193125-26-099489
**Filing Date:** 2026-3
**Character Count:** 23533
**Document Hash:** fe8f26d17c4ac2672f5352f45085a63a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-099489.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001193125-26-099489

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**EFFECTIVENESS DATE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ImageneBio, Inc.
- **CENTRAL INDEX KEY:** 0001835579
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811697316
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294174
- **FILM NUMBER:** 26737471

**BUSINESS ADDRESS:**
- **STREET 1:** 12526 HIGH BLUFF DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 857-343-8292

**MAIL ADDRESS:**
- **STREET 1:** 12526 HIGH BLUFF DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ikena Oncology, Inc.
- **DATE OF NAME CHANGE:** 20201208

**As filed with the Securities and Exchange Commission on March 10, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## IMAGENEBIO, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **81-1697316** |
| **(State or Other Jurisdiction of**<br> **Incorporation or Organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**12526 High Bluff Drive, Suite 345** 

**San Diego, CA 92130** 

**(858) 345-6265**

**(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)** 

**ImageneBio, Inc. 2025 Equity Incentive Plan** 

**ImageneBio, Inc. 2025 Employee Stock Purchase Plan** 

**ImageneBio, Inc. 2025 Equity Inducement Plan** 

**(Full title of the plans)** 

**Kristin Yarema, Ph.D.** 

**Chief Executive Officer** 

**12526 High Bluff Drive, Suite 345** 

**San Diego, CA 92130** 

**(858) 345-6265**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Thomas A. Coll, Esq.** 

**Asa M. Henin, Esq.** 

**Brittany K. Wightman, Esq.** 

**Cooley LLP** 

**10265 Science Center Drive** 

**San Diego, CA 92121** 

**(858) 550-6000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement on Form S-8 (this "Registration Statement") is being filed by ImageneBio, Inc. (the "Registrant") for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans are effective. The Registrant previously registered its shares of common stock, par value $0.001 per share (the "Common Stock"), for issuance under the Registrant's 2025 Equity Incentive Plan (the "2025 Plan"), the Registrant's 2025 Employee Stock Purchase Plan (the "ESPP") and the Registrant's 2025 Equity Inducement Plan (the "Inducement Plan") under the Registrant's Registration Statement on Form S-8 (the "Prior Registration Statement") filed with the Securities and Exchange Commission (the "Commission") on November 12, 2025 (File No.[333-291449](http://www.sec.gov/Archives/edgar/data/1835579/000119312525276225/d18296ds8.htm)). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference, except that the provisions contained in Part II of such Prior Registration Statement are modified or supplemented, as the case may be, as set forth in this Registration Statement.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Certain Documents by Reference.** 

The following documents filed by the Registrant with the Commission are incorporated by reference to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registrant's Annual Report on <u>[Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001835579/000119312526099434/ima-20251231.htm)</u> for the fiscal year ended December 31, 2025, filed with the Commission on March 10, 2026 (the "2025 Annual Report");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Registrant's Current Report on Form 8-K filed with the
Commission on [February 17, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001835579/000119312526054684/d18298d8k.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the description of the Registrant's Capital Stock filed as <u>[Exhibit 4.4](http://www.sec.gov/Archives/edgar/data/1835579/000119312526099434/ima-ex4_4.htm)</u> to the 2025 Annual Report.

In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the Commission), prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

Any statement, including financial statements, contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or therein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Exhibit Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Fifth Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-40287) filed with the Commission on March 30, 2021).](http://www.sec.gov/Archives/edgar/data/1835579/000119312521100292/d108142dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of the Registrant, dated July 25, 2025 (Stock Split Amendment) (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-40287) filed with the Commission on July 29, 2025).](http://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/d66290dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of the Registrant, dated July 25, 2025 (Name Change Amendment) (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-40287) filed with the Commission on July 29, 2025).](http://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/d66290dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4 | [Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-40287) filed with the Commission on March 30, 2021).](http://www.sec.gov/Archives/edgar/data/1835579/000119312521100292/d108142dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Cooley LLP.](d107848dex51.htm) |
| 23.1 | [Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.](d107848dex231.htm) |
| 23.2 | [Consent of Cooley LLP (included in Exhibit 5.1).](d107848dex51.htm) |
| 24.1 | [Power of Attorney (included on the signature page to this Registration Statement).](#tx107848_1) |
| 99.1 | [The Registrant's 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-290108) filed with the Commission on September 8, 2025).](http://www.sec.gov/Archives/edgar/data/0001835579/000119312525198360/d931520dex102.htm) |
| 99.2 | [Forms of Option Award Notice, Option Agreement and Notice of Exercise under the Registrant's 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.21 to the Registrant's Current Report on Form 8-K (File No. 001-40287) filed with the Commission on July 29, 2025).](http://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/d66290dex1021.htm) |
| 99.3 | [Forms of Restricted Stock Unit Grant Notice and Unit Award Agreement under the Registrant's 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 to the Registrant's Current Report on Form 8-K (File No. 001-40287) filed with the Commission on July 29, 2025).](http://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/d66290dex1022.htm) |
| 99.4 | [The Registrant's 2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Registration Statement on Form S-1 (File No. 333-290108) filed with the Commission on September 8, 2025).](http://www.sec.gov/Archives/edgar/data/0001835579/000119312525198360/d931520dex105.htm) |
| 99.5 | [The Registrant's 2025 Equity Inducement Plan and Forms of Stock Option Grant Notice, Option Agreement, and Notice of Exercise and Forms of RSU Grant Notice and RSU Agreement thereunder (incorporated by reference to Exhibit 99.1 to the Registrant's Current Report on Form 8-K (File No. 001-40287) filed with the SEC on August 1, 2025).](http://www.sec.gov/Archives/edgar/data/1835579/000119312525171747/d96158dex991.htm) |
| 107.1 | [Filing Fee Table.](d107848dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on the 10th day of March 2026.

---

| | |
|:---|:---|
| **IMAGENEBIO, INC.** | **IMAGENEBIO, INC.** |
| By: | /s/ Kristin Yarema |
| Name: | Kristin Yarema, Ph.D. |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kristin Yarema, Ph.D. the individual's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Kristin Yarema<br> Kristin Yarema, Ph.D. | Chief Executive Officer and Director<br> (Principal Executive Officer and Interim Principal Financial Officer) | March 10, 2026 |
| /s/ Erin Butler<br> Erin Butler | Senior Vice President, Finance and Administration<br> (Principal Accounting Officer) | March 10, 2026 |
| /s/ Jonathan Jian Wang<br> Jonathan Jian Wang, Ph.D., MBA | Chair of the Board | March 10, 2026 |
| /s/ David P. Bonita<br> David P. Bonita, M.D. | Lead Independent Director | March 10, 2026 |
| /s/ Joseph P. Slattery<br> Joseph P. Slattery | Director | March 10, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g107848dsp1aa.jpg)

Asa M. Henin

+1 858 550 6104

ahenin@cooley.com

March 10, 2026

ImageneBio, Inc.

12526 High Bluff Drive, Suite 345

San Diego, California 92130

**Re: Registration Statement on Form S-8** 

Ladies and Gentlemen:

We have acted as counsel to ImageneBio, Inc., a Delaware corporation (the "***Company***"), in connection with the filing of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "**Commission**") covering the offering of up to 1,670,897 shares (the "***Shares***") of the Company's Common Stock, par value $0.001 per share ("***Common Stock***"), consisting of (a) 559,081 shares of Common Stock issuable pursuant to the Company's 2025 Equity Incentive Plan (the "***2025 Plan***"), (b) 111,816 shares of Common Stock issuable pursuant to the Company's 2025 Employee Stock Purchase Plan (the "***ESPP***") and (c) 1,000,000 shares of Common Stock issuable pursuant to the Company's 2025 Equity Inducement Plan (the "***Inducement Plan***" and together with the 2025 Plan and ESPP, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectuses, (b) the Plans, (c) the Company's certificate of incorporation and bylaws, each as currently in effect and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

*[Remainder of Page Intentionally Blank]* 

------

![LOGO](g107848dsp1aa.jpg)

Page Two

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| Cooley LLP | Cooley LLP |
| By: | /s/ Asa M. Henin |
|  | Asa M. Henin |

---

## Exhibit 23.1

**Exhibit 23.1** 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of ImageneBio, Inc. of our report dated March 10, 2026 relating to the financial statements, which appears in ImageneBio. Inc's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP

San Diego, California

March 10, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**ImageneBio, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | 2025 Equity Incentive Plan, Common Stock, $0.001 per share | Other | 559081 | $5.93 | $3315350.33 | 0.0001381 | $457.85 |
| 2 | Equity | 2025 Employee Stock Purchase Plan, Common Stock, $0.001 per share | Other | 111816 | $5.04 | $563552.64 | 0.0001381 | $77.83 |
| 3 | Equity | 2025 Equity Inducement Plan, Common Stock $0.001 per share | Other | 1000000 | $5.93 | $5930000.00 | 0.0001381 | $818.94 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $9808902.97  |  | $1354.62  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $1354.62  |

---

 **Offering Note** <br>

<sup>1</sup> The amount registered represents 559,081 additional shares of ImageneBio, Inc's (the "Registrant's") common stock, par value $0.001 per share (the "Common Stock") that were automatically added to the shares authorized for issuance under the Registrant's 2025 Equity Incentive Plan (the "2025 Plan") on January 1, 2026 pursuant to an "evergreen" provision contained in the 2025 Plan. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), the Registration Statement on Form S-8 to which this exhibit is a part (the "Registration Statement") shall also cover any additional shares of Common Stock that become issuable under the 2025 Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price is estimated in accordance with Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee, and are based upon the average of the high and low prices of the Common Stock on March 6, 2026 (the "Average Price"), as reported on the Nasdaq Capital Market. Pursuant to the evergreen provision, on January 1 of each year for a period of ten years commencing on January 1, 2026 and ending on (and including) January 1, 2035, the number of shares authorized for issuance under the 2025 Plan will be automatically increased in an amount equal to 5% of the total number of shares of Capital Stock outstanding (as defined in the 2025 Plan) on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Registrant's board of directors (the "Board") may act prior to January 1 of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock.

<sup>2</sup> The amount registered represents 111,816 additional shares of Common Stock that were automatically added to the shares authorized under the Registrant's 2025 Employee Stock Purchase Plan (the "ESPP") on January 1, 2026 pursuant to an "evergreen" provision contained in the ESPP. Pursuant to Rule 416(a) under the Securities Act, the Registration Statement shall also cover any additional shares of Common Stock that become issuable under the ESPP by reason of any stock dividend, stock split, recapitalization or other similar transaction. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price is estimated in accordance with Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee, and are calculated on the basis of the Average Price, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the ESPP. Pursuant to the evergreen provision, on January 1 of each year for a period of up to ten years, beginning on January 1, 2026 and ending on (and including) January 1, 2035, the number of shares authorized for issuance under the ESPP will be automatically increased by an amount equal to the lesser of (i) 1% of the total number of shares of Capital Stock outstanding (as defined in the ESPP) on December 31 of the preceding calendar year, and (ii) 227,944 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will be no January 1 increase in the share reserve for such calendar year or that the increase for such year will be a lesser number of shares.

<sup>3</sup> The amount registered represents the 1,000,000 shares of Common Stock added to the reserve of shares under the Registrant's 2025 Equity Inducement Plan (the "Inducement Plan") as inducement grants. Pursuant to Rule 416(a) under the Securities Act, the Registration Statement shall also cover any additional shares of Common Stock that become issuable under the Inducement Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price are estimated pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee, and are based upon the Average Price.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---